FTC insists generics ANI and Novitium divest IP before merger

The Federal Trade Commission (FTC) has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Insulin pump rivals face off in major trade secrets dispute hearing

8 January 2026 Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.

Americas

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

8 January 2026 Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.

Europe

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals

8 January 2026 An inaugural, first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

More features

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

FTC insists generics ANI and Novitium divest IP before merger

More on this story

Editor's picks

Editor's picks

More features